Prolonged IDO activation and the resulting increase in neurotoxic KP metabolites drive systemic and neuroinflammation in depression, leading to impaired neuroplasticity, decreased hippocampal neurogenesis, and disrupted dopamine transmission, which manifest as classic depressive symptoms like motivational deficits and anhedonia [54]. This evidence concerns the gene IDO1 and depressive symptom measurement.